secukinumab

Home
Ligands
secukinumab

GtoPdb Ligand ID: 8078

Synonyms: AIN 457 | AIN457 | Cosentyx® | NVP-AIN457

secukinumab is an approved drug (Japan (2014), FDA and EMA (2015))

Comment: Peptide sequences for this antibody are available from its IMGT/mAb-DB entry.
This antibody is the subject of patent US7807155 [2].

References
1. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M et al.. (2015) Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis. N Engl J Med, 373 (26): 2534-48. [PMID:26699169]
2. Di Padova FE, Gram H, Hofstetter H, Jeschke M, Rondeau J-M, Van Den Berg W. (2010) IL-17 antagonistic antibodies. Patent number: US7807155. Assignee: Novartis Ag. Priority date: 05/08/2004. Publication date: 05/10/2010.
3. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. (2014) The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes. Glia, 62 (5): 725-35. [PMID:24677511]
4. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T et al.. (2014) One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol, 41 (3): 414-21. [PMID:24429175]
5. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group et al.. (2010) Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med, 2 (52): 52ra72. [PMID:20926833]
6. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B et al.. (2014) Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med, 371 (4): 326-38. [PMID:25007392]
7. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB et al.. (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, 386 (9999): 1137-46. [PMID:26135703]
8. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J et al.. (2015) Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis. N Engl J Med, 373 (14): 1329-39. [PMID:26422723]
9. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup. (2014) Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol, 41 (12): 1039-46. [PMID:25354738]
10. Toussirot E. (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets, 11 (2): 159-68. [PMID:22280236]
11. van den Berg WB, McInnes IB. (2013) Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics. Semin Arthritis Rheum, 43 (2): 158-70. [PMID:24157091]

References

1. Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M et al.. (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
N Engl J Med, 373 (26): 2534-48. [PMID:26699169]

2. Di Padova FE, Gram H, Hofstetter H, Jeschke M, Rondeau J-M, Van Den Berg W. (2010)
IL-17 antagonistic antibodies.
Patent number: US7807155. Assignee: Novartis Ag. Priority date: 05/08/2004. Publication date: 05/10/2010.

3. Elain G, Jeanneau K, Rutkowska A, Mir AK, Dev KK. (2014)
The selective anti-IL17A monoclonal antibody secukinumab (AIN457) attenuates IL17A-induced levels of IL6 in human astrocytes.
Glia, 62 (5): 725-35. [PMID:24677511]

4. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T et al.. (2014)
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
J Rheumatol, 41 (3): 414-21. [PMID:24429175]

5. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, Antoni C, Draelos Z, Gold MH, Psoriasis Study Group et al.. (2010)
Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.
Sci Transl Med, 2 (52): 52ra72. [PMID:20926833]

6. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B et al.. (2014)
Secukinumab in plaque psoriasis--results of two phase 3 trials.
N Engl J Med, 371 (4): 326-38. [PMID:25007392]

7. McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, van der Heijde D, Landewé R, Conaghan PG, Gottlieb AB et al.. (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet, 386 (9999): 1137-46. [PMID:26135703]

8. Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, Landewé R, Nash P, Pricop L, Yuan J et al.. (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
N Engl J Med, 373 (14): 1329-39. [PMID:26422723]

9. Ohtsuki M, Morita A, Abe M, Takahashi H, Seko N, Karpov A, Shima T, Papavassilis C, Nakagawa H, ERASURE Study Japanese subgroup. (2014)
Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
J Dermatol, 41 (12): 1039-46. [PMID:25354738]

10. Toussirot E. (2012)
The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases.
Inflamm Allergy Drug Targets, 11 (2): 159-68. [PMID:22280236]

11. van den Berg WB, McInnes IB. (2013)
Th17 cells and IL-17 a--focus on immunopathogenesis and immunotherapeutics.
Semin Arthritis Rheum, 43 (2): 158-70. [PMID:24157091]